Industry News

TNK Therapeutics, Inc, a subsidiary of Sorrento Therapeutics, Inc  has entered into a binding term sheet to acquire Virttu Biologics Limited ("Virttu").

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, announced the issuance of a United States patent covering Oxaydo (oxycodone HCI, USP) tablets for oral use only–CII. Egalet licensed Oxaydo from Acura Pharmaceuticals and launched the product in the United States in September 2015.

NeuroMetrix, Inc. announced  that Quell® Wearable Pain Relief Technology™ will be featured for the second year in a row at the American Society for Regional Anesthesia's Annual Pain Medicine Meeting to be held November 17-19 in San Diego, CA.

Amplyx Pharmaceuticals, a company developing novel antifungal agents for life-threatening fungal infections, announced  that the U.S. Food and Drug Administration (FDA) Office of Orphan Product Development has granted orphan drug designation to APX001, the company’s lead drug candidate. APX001 has received orphan drug designation for four distinct indications: the treatment of invasive candidiasis, invasive aspergillosis, coccidioidomycosis, and rare mold infections caused by Scedosporium spp., Fusarium spp., and Mucorales fungi (including Mucor spp., and Rhizopus spp.).

Allergan plc  announced a national partnership with Amy Dixon, world champion paratriathlete and irritable bowel syndrome with diarrhea (IBS-D) patient. Through this partnership, Dixon will serve as a spokesperson to share her story with fellow IBS-D sufferers and healthcare providers, with the goal of improving dialogue between patients and their physicians about this condition and impact on patients' lives.

Janssen Research & Development, LLC (Janssen) announced positive efficacy and safety results from a Phase 2 study investigating guselkumab, an anti-interleukin (IL)-23 monoclonal antibody administered by subcutaneous injection, for the treatment of active psoriatic arthritis. According to findings presented at the 2016 ACR/ARHP Annual Meeting, 58 percent of patients receiving guselkumab achieved at least a 20 percent improvement in signs and symptoms of disease (ACR 20) at week 24, the study’s primary endpoint, compared with 18.4 percent of patients receiving placebo (P < 0.001).

NeuroMetrix, Inc. , a commercial stage, innovation driven healthcare company, will introduce DPNCheck, a diagnostic test for peripheral neuropathy at the 20th Scientific Meeting of the Chinese Diabetes Society during November 16-19, 2016 in Xiamen, Fujian, China.

[adsense:336x280:8701650588]

Janssen-Cilag International NV (Janssen) announced that the European Commission (EC) has approved the use of Stelara (ustekinumab) for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFa) antagonist or have medical contraindications to such therapies.

Cellnovo Group announces  that it has filed for 510(k) approval with the US Food and Drug Administration (FDA) for marketing clearance of the Company's diabetes management system.

Janssen Research & Development, LLC (Janssen) announced  new findings from a pivotal Phase 3 study showing the efficacy and safety profile of the intravenously administered anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI ARIA® (golimumab) in the treatment of active ankylosing spondylitis (AS).